Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dasatinib

dasatinib

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dasatinib

79 trials tracked of dasatinib: 7 in phase 3 or 4 and 2 with published results. The most-cited published study has 248 citations.

79Trials tracked
7Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 64 Phase 1 5 Other / NA 3
  1. Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 248 cited
  2. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Completed · 84 cited
  3. Phase 4 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed
  4. Phase 3 A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Completed
  5. Phase 3 Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer Completed
  6. Phase 3 Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML Completed
Show 44 more trials
  1. Phase 3 Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML Completed
  2. Phase 2 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed
  3. Phase 2 Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis Completed
  4. Phase 2 A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed
  5. Phase 2 Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia Completed
  6. Phase 2 Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma Completed
  7. Phase 2 Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib Completed
  8. Phase 2 Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) Completed
  9. Phase 2 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma Completed
  10. Phase 2 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed
  11. Phase 2 Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Completed
  12. Phase 2 Phase II Dasatinib Study in Advanced Breast Cancer Completed
  13. Phase 2 Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Completed
  14. Phase 2 Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer Completed
  15. Phase 2 Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects Completed
  16. Phase 2 Treatment of Adult Ph+ LAL With BMS-354825 Completed
  17. Phase 2 A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer Completed
  18. Phase 2 Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer Completed
  19. Phase 2 Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
  20. Phase 2 Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  21. Phase 2 Trial of Dasatinib in Advanced Sarcomas Completed
  22. Phase 2 Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma Completed
  23. Phase 2 S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone Completed
  24. Phase 2 Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Completed
  25. Phase 2 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Completed
  26. Phase 2 Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma Completed
  27. Phase 2 Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer Completed
  28. Phase 2 Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Completed
  29. Phase 2 Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib Completed
  30. Phase 2 Rollover Study of BMS-354825 in Patients With CML and Ph+ALL Completed
  31. Phase 2 Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies Completed
  32. Phase 2 Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer Completed
  33. Phase 2 Dasatinib in Treating Patients With Metastatic Pancreatic Cancer Completed
  34. Phase 2 A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib Completed
  35. Phase 2 Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer Completed
  36. Phase 2 A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Completed
  37. Phase 2 Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Completed
  38. Phase 2 Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease Completed
  39. Phase 2 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed
  40. Phase 2 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Completed
  41. Phase 2 Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer Completed
  42. Phase 2 Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer Completed
  43. Phase 2 Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib Completed
  44. Phase 2 Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed

Showing the 50 most-cited and recently-updated of 79 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis
Oncology
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis New combo drug stops leukemia that fought back against two drugs
This case report describes a single CML patient who relapsed with B lymphoblastic blast crisis harboring a T315I mutation and a novel e6a3 B…
A new three-drug mix stops a tough leukemia that grew stronger after two drugs failed to control it.
medRxiv Apr 24, 2026
Dasatinib Added to Intensive Chemotherapy Fails to Improve Survival in CBF-AML
Oncology RCT
Dasatinib Added to Intensive Chemotherapy Fails to Improve Survival in CBF-AML Adding Dasatinib to Chemo Does Not Help CBF-AML Patients
A phase 3 randomized trial in 202 adults with core-binding factor acute myeloid leukemia (CBF-AML) found adding dasatinib to intensive chemo…
Adding dasatinib to standard chemotherapy did not improve survival for adults with core-binding factor acute myeloid leukemia and increased …
Blood Apr 10, 2026
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04
Hematology Phase II
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04 Reduced transplant use showed similar outcomes in children with Philadelphia chromosome-positive leukemia
This single-arm Phase 2 trial evaluated chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease in 41 eligibl…
Children with a specific leukemia type achieved similar survival rates without stem cell transplants, offering a less intensive treatment op…
Apr 8, 2026
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty
Infectious Disease Phase II
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty Can a New Drug Combination Help Older Adults with HIV Regain Strength?
Phase II trial of dasatinib and quercetin (D+Q) in 82 HIV+ frail/prefrail adults shows potential in improving gait speed.
A new trial tests if two drugs help older adults with HIV regain strength and walk better after years of frailty.
CT.gov Mar 27, 2026